However, despite the previously mentioned limitations, our results suggest that, with the adequate use of G-CSF in patients with breast cancer treated with anthracyclines plus taxane-based schedules in the adjuvant setting, optimal chemotherapy administration could be achieved in almost all patients. Here, CSF3 is linked to breast cancer.